{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T00:33:08Z","timestamp":1791678788301,"version":"4.3.4"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00520-026-10945-y","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:12:01Z","timestamp":1783059121000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Diagnosis and management of immune checkpoint inhibitor\u2013induced dry mouth and salivary gland dysfunction in oncology patients: a systematic review"],"prefix":"10.1007","volume":"34","author":[{"given":"Rosa Mar\u00eda","family":"L\u00f3pez-Pintor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Gonz\u00e1lez-Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"Musella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan Roger","family":"Santos-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Rodr\u00edguez-Molinero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"10945_CR1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","volume":"76","author":"LC Cappelli","year":"2017","unstructured":"Cappelli LC, Gutierrez AK, Baer AN, Albayda J, Manno RL, Haque U et al (2017) Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 76:43\u201350","journal-title":"Ann Rheum Dis"},{"key":"10945_CR2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158\u2013168","journal-title":"N Engl J Med"},{"key":"10945_CR3","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.autrev.2018.01.010","volume":"17","author":"M Tocut","year":"2018","unstructured":"Tocut M, Brenner R, Zandman-Goddard G (2018) Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev 17:610\u2013616","journal-title":"Autoimmun Rev"},{"key":"10945_CR4","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12935-023-02902-0","volume":"23","author":"HE Marei","year":"2023","unstructured":"Marei HE, Hasan A, Pozzoli G, Cenciarelli C (2023) Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired. Cancer Cell Int 23:64","journal-title":"Cancer Cell Int"},{"key":"10945_CR5","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H et al (2022) Immune Checkpoint Inhibitors in Cancer Therapy. Curr Oncol 29:3044\u20133060","journal-title":"Curr Oncol"},{"key":"10945_CR6","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.23177","volume":"69","author":"LC Cappelli","year":"2017","unstructured":"Cappelli LC, Gutierrez AK, Bingham CO 3rd, Shah AA (2017) Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature. Arthritis Care Res (Hoboken) 69:1751\u20131763","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10945_CR7","doi-asserted-by":"crossref","first-page":"1684475","DOI":"10.3389\/fphar.2025.1684475","volume":"16","author":"Y Zou","year":"2025","unstructured":"Zou Y, Li Q, Zhou L, Lu Y, Wei H, Zhou Y et al (2025) Association between immune check point inhibitors and digestive system inflammatory adverse reactions: evidence from pharmacovigilance analysis and systematic review. Front Pharmacol 16:1684475","journal-title":"Front Pharmacol"},{"key":"10945_CR8","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","volume":"77","author":"M Kostine","year":"2018","unstructured":"Kostine M, Rouxel L, Barnetche T, Veillon R, Martin F, Dutriaux C et al (2018) Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis 77:393\u2013398","journal-title":"Ann Rheum Dis"},{"key":"10945_CR9","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.autrev.2018.01.003","volume":"17","author":"M Lidar","year":"2018","unstructured":"Lidar M, Giat E, Garelick D, Horowitz Y, Amital H, Steinberg-Silman Y et al (2018) Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev 17:284\u2013289","journal-title":"Autoimmun Rev"},{"key":"10945_CR10","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1002\/hed.27646","volume":"46","author":"K Al-Eryani","year":"2024","unstructured":"Al-Eryani K, Epstein JB, Monreal AV, Villa A (2024) Orofacial complications from immune checkpoint inhibitors: a retrospective analysis from two academic medical centers. Head Neck 46:1865\u20131872","journal-title":"Head Neck"},{"key":"10945_CR11","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1158\/1078-0432.CCR-14-2468","volume":"21","author":"GT Gibney","year":"2015","unstructured":"Gibney GT, Kudchadkar RR, DeConti RC, Thebeau MS, Czupryn MP, Tetteh L et al (2015) Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res 21:712\u2013720","journal-title":"Clin Cancer Res"},{"key":"10945_CR12","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1111\/odi.14000","volume":"28","author":"JA Harris","year":"2022","unstructured":"Harris JA, Huang K, Miloslavsky E, Hanna GJ (2022) Sicca syndrome associated with immune checkpoint inhibitor therapy. Oral Dis 28:2083\u20132092","journal-title":"Oral Dis"},{"key":"10945_CR13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","volume":"16","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Mazi\u00e8res J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ et al (2015) Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 16:257\u2013265","journal-title":"Lancet Oncol"},{"key":"10945_CR14","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/cncr.33436","volume":"127","author":"Y Xu","year":"2021","unstructured":"Xu Y, Wen N, Sonis ST, Villa A (2021) Oral side effects of immune checkpoint inhibitor therapy (ICIT): An analysis of 4683 patients receiving ICIT for malignancies at Massachusetts General Hospital, Brigham & Women\u2019s Hospital, and the Dana-Farber Cancer Institute, 2011 to 2019. Cancer 127:1796\u20131804","journal-title":"Cancer"},{"key":"10945_CR15","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","volume":"32","author":"SL Topalian","year":"2014","unstructured":"Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH et al (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32:1020\u20131030","journal-title":"J Clin Oncol"},{"key":"10945_CR16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2017.05.032","volume":"82","author":"S Le Burel","year":"2017","unstructured":"Le Burel S, Champiat S, Mateus C, Marabelle A, Michot JM, Robert C et al (2017) Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1\/anti-programmed cell death-ligand 1 agents: a single-centre pharmacovigilance database analysis. Eur J Cancer 82:34\u201344","journal-title":"Eur J Cancer"},{"issue":"3","key":"10945_CR17","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3390\/cancers12030738","volume":"12","author":"RK Vaddepally","year":"2020","unstructured":"Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB (2020) Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel) 12(3):738","journal-title":"Cancers (Basel)"},{"key":"10945_CR18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.7150\/ijms.17718","volume":"14","author":"T Both","year":"2017","unstructured":"Both T, Dalm VA, van Hagen PM, van Daele PL (2017) Reviewing primary Sj\u00f6gren\u2019s syndrome: beyond the dryness - From pathophysiology to diagnosis and treatment. Int J Med Sci 14:191\u2013200","journal-title":"Int J Med Sci"},{"key":"10945_CR19","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1634\/theoncologist.2018-0823","volume":"24","author":"BM Warner","year":"2019","unstructured":"Warner BM, Baer AN, Lipson EJ, Allen C, Hinrichs C, Rajan A et al (2019) Sicca syndrome associated with immune checkpoint inhibitor therapy. Oncologist 24:1259\u20131269","journal-title":"Oncologist"},{"key":"10945_CR20","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1080\/1744666X.2024.2370327","volume":"20","author":"SG Pasoto","year":"2024","unstructured":"Pasoto SG, Franco AS, Silva CA, Bonfa E (2024) Sicca syndrome\/Sj\u00f6gren\u2019s disease associated with cancer immunotherapy: a narrative review on clinical presentation, biomarkers, and management. Expert Rev Clin Immunol 20:1149\u20131167","journal-title":"Expert Rev Clin Immunol"},{"key":"10945_CR21","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/jdv.17855","volume":"36","author":"Z Apalla","year":"2022","unstructured":"Apalla Z, Nikolaou V, Fattore D, Fabbrocini G, Freites-Martinez A, Sollena P et al (2022) European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force \u201cDermatology for cancer patients\u201d position statement. J Eur Acad Dermatol Venereol 36:332\u2013350","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10945_CR22","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1200\/OP-24-00812","volume":"21","author":"A Villa","year":"2025","unstructured":"Villa A, Schneider BJ, Lacchetti C, Oliver TK, Peterson DE (2025) Oral immune-related adverse events secondary to immune checkpoint inhibitors: call to action. JCO Oncol Pract 21:1073\u20131078","journal-title":"JCO Oncol Pract"},{"key":"10945_CR23","first-page":"851","volume":"33","author":"ER Fregnani","year":"2025","unstructured":"Fregnani ER, Epstein JB, Blijlevens NMA, Yarom N, Villa A, Raber-Durlacher JE et al (2025) MASCC\/ISOO clinical practice statement: management of oral complications of immunotherapy. Support Care Cancer 33:851","journal-title":"Support Care Cancer"},{"key":"10945_CR24","first-page":"551","volume":"32","author":"C Hong","year":"2024","unstructured":"Hong C, Epstein JB, Jensen SB, Gueiros LA, van Leeuwen SJM, Kandwal A et al (2024) MASCC\/ISOO clinical practice statement: clinical assessment of salivary gland hypofunction and xerostomia in cancer patients. Support Care Cancer 32:551","journal-title":"Support Care Cancer"},{"key":"10945_CR25","first-page":"548","volume":"32","author":"C Hong","year":"2024","unstructured":"Hong C, Jensen SB, Vissink A, Bonomo P, Santos-Silva AR, Gueiros LA et al (2024) MASCC\/ISOO clinical practice statement: Management of salivary gland hypofunction and xerostomia in cancer patients. Support Care Cancer 32:548","journal-title":"Support Care Cancer"},{"key":"10945_CR26","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"10945_CR27","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrd3463","volume":"10","author":"VK Sondak","year":"2011","unstructured":"Sondak VK, Smalley KS, Kudchadkar R, Grippon S, Kirkpatrick P (2011) Ipilimumab. Nat Rev Drug Discov 10:411\u2013412","journal-title":"Nat Rev Drug Discov"},{"key":"10945_CR28","unstructured":"Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, Currie M, Qureshi R, Mattis P, Lisy K, Mu P-F (2017) Chapter 7: Systematic reviews of etiology and risk. In: Aromataris E, Munn Z (eds). Joanna Briggs Institute Reviewer's Manual. The Joanna Briggs Institute, 2017. Available from https:\/\/reviewersmanual.joannabriggs.org\/"},{"key":"10945_CR29","first-page":"2127","volume":"18","author":"Z Munn","year":"2020","unstructured":"Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A et al (2020) Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth 18:2127\u20132133","journal-title":"JBI Evid Synth"},{"key":"10945_CR30","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, Tugwell P (2025) The newcastle\u2013ottawa scale (NOS) for assessing the quality of non-randomised studies in meta-analyses. Ottawa Hospital Research Institute. Available from: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed 29 Dec 2025"},{"key":"10945_CR31","unstructured":"McPheeters ML, Kripalani S, Peterson NB et al (2012) Closing the quality gap: revisiting the state of the science. Vol. 3: Quality improvement interventions to address health disparities. Evidence Report\/Technology Assessment (Full Report). Rockville (MD): Agency for Healthcare Research and Quality. Report No.: 208. 1\u2013475."},{"key":"10945_CR32","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1007\/s10067-024-07177-y","volume":"43","author":"C Bourgeois","year":"2024","unstructured":"Bourgeois C, Sanchez Lucas M, Rodriguez Merlos P, Nieto-Gonzalez JC, Alvaro-Gracia JM, Molina-Collada J (2024) Salivary gland ultrasound features in sicca syndrome secondary to immunotherapy with checkpoint inhibitors. Clin Rheumatol 43:3999\u20134001","journal-title":"Clin Rheumatol"},{"key":"10945_CR33","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1177\/0022034519850564","volume":"98","author":"PD Burbelo","year":"2019","unstructured":"Burbelo PD, Ferre EMN, Chaturvedi A, Chiorini JA, Alevizos I, Lionakis MS et al (2019) Profiling autoantibodies against salivary proteins in sicca conditions. J Dent Res 98:772\u2013778","journal-title":"J Dent Res"},{"key":"10945_CR34","first-page":"1681","volume":"30","author":"H Bustillos","year":"2022","unstructured":"Bustillos H, Indorf A, Alwan L, Thompson J, Jung L (2022) Xerostomia: an immunotherapy-related adverse effect in cancer patients. Support Care Cancer 30:1681\u20131687","journal-title":"Support Care Cancer"},{"key":"10945_CR35","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1159\/000532098","volume":"16","author":"A Caeyman","year":"2023","unstructured":"Caeyman A, Vandekerckhove O, Pat K, Wynants J, Weytjens K, de Wergifosse I et al (2023) Sjogren\u2019s syndrome caused by PD-1 inhibition in a lung cancer patient. Case Rep Oncol 16:1095\u20131099","journal-title":"Case Rep Oncol"},{"key":"10945_CR36","doi-asserted-by":"crossref","first-page":"e000412","DOI":"10.1136\/rmdopen-2016-000412","volume":"3","author":"C Calabrese","year":"2017","unstructured":"Calabrese C, Kirchner E, Kontzias A, Velcheti V, Calabrese LH (2017) Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity. RMD Open 3:e000412","journal-title":"RMD Open"},{"key":"10945_CR37","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1093\/rheumatology\/keab698","volume":"61","author":"HJ Clark","year":"2021","unstructured":"Clark HJ, Fong PCC, Ng KPL (2021) Clinical and serological resolution of pembrolizumab associated Sjogren\u2019s syndrome: long-term follow-up. Rheumatology (Oxford) 61:e22\u2013e24","journal-title":"Rheumatology (Oxford)"},{"key":"10945_CR38","doi-asserted-by":"crossref","first-page":"486","DOI":"10.46883\/ONC.2021.3508.0486","volume":"35","author":"E Conde-Flores","year":"2021","unstructured":"Conde-Flores E, Remolina-Bonilla Y, Castro-Alonso F, Martinez-Ibarra N, Hernandez-Molina G, Chapa-Ibarguengoitia M et al (2021) Sjogren syndrome induced by immune checkpoint inhibitors in a patient with advanced renal cell carcinoma. Oncology (Williston Park) 35:486\u2013490","journal-title":"Oncology (Williston Park)"},{"issue":"19","key":"10945_CR39","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.3390\/cancers15194781","volume":"15","author":"S Elad","year":"2023","unstructured":"Elad S, Yarom N, Zadik Y (2023) Immunotherapy-related oral adverse effects: immediate sequelae, chronicity and secondary cancer. Cancers (Basel) 15(19):4781","journal-title":"Cancers (Basel)"},{"key":"10945_CR40","first-page":"21","volume":"13","author":"A Glavina","year":"2023","unstructured":"Glavina A, Tadin A (2023) Sicca symptoms and sialoadenitis as immune-related adverse events of nivolumab treatment in renal malignancy. MOJ Clin Med Case Rep 13:21\u201323","journal-title":"MOJ Clin Med Case Rep"},{"key":"10945_CR41","doi-asserted-by":"crossref","first-page":"612","DOI":"10.55563\/clinexprheumatol\/o5nvgv","volume":"39","author":"I Gonzalez-Maz\u00f3n","year":"2021","unstructured":"Gonzalez-Maz\u00f3n I, S\u00e1nchez-Bilbao L, Mart\u00edn-Varillas JL, Garc\u00eda-Casta\u00f1o A, Delgado-Ruiz M, Bernat Pi\u00f1a I et al (2021) Immune-related adverse events in patients with solid-organ tumours treated with immunotherapy: a 3-year study of 102 cases from a single centre. Clin Exp Rheumatol 39:612\u2013620","journal-title":"Clin Exp Rheumatol"},{"key":"10945_CR42","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.2169\/internalmedicine.4701-20","volume":"59","author":"T Higashi","year":"2020","unstructured":"Higashi T, Miyamoto H, Yoshida R, Furuta Y, Nagaoka K, Naoe H et al (2020) Sjogren\u2019s syndrome as an immune-related adverse event of nivolumab treatment for gastric cancer. Intern Med 59:2499\u20132504","journal-title":"Intern Med"},{"key":"10945_CR43","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","volume":"60","author":"L Hofmann","year":"2016","unstructured":"Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S et al (2016) Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 60:190\u2013209","journal-title":"Eur J Cancer"},{"key":"10945_CR44","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s11282-020-00480-9","volume":"37","author":"K Katsura","year":"2021","unstructured":"Katsura K, Funayama S, Ito K, Nohno K, Kaneko N, Takamura M et al (2021) Radiological imaging features of the salivary glands in xerostomia induced by an immune checkpoint inhibitor. Oral Radiol 37:531\u2013536","journal-title":"Oral Radiol"},{"key":"10945_CR45","volume":"50","author":"K Kumagai","year":"2024","unstructured":"Kumagai K, Baba T, Fukushima T, Tabata E, Nakazawa A, Hagiwara E et al (2024) A case of sialadenitis observed as an irAE of atezolizumab: A case report. Respir Med Case Rep 50:102068","journal-title":"Respir Med Case Rep"},{"key":"10945_CR46","volume":"41","author":"I Nakajima","year":"2025","unstructured":"Nakajima I, Yoshino K, Miyake M, Takeuchi K, Tsuji H (2025) Dacryoadenitis and Sjogren-like Symptoms Caused by Nivolumab. Ophthalmic Plast Reconstr Surg 41:e109","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10945_CR47","doi-asserted-by":"crossref","unstructured":"Narvaez J, Juarez-Lopez P, J LL, Narvaez JA, Palmero R, Garcia Del Muro X, et al (2018) Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: fasciitis with myositis syndrome as a new complication of immunotherapy. Autoimmun Rev 17:1040\u20135","DOI":"10.1016\/j.autrev.2018.05.002"},{"key":"10945_CR48","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.1634\/theoncologist.2019-0467","volume":"25","author":"A Ortiz Brugu\u00e9s","year":"2020","unstructured":"Ortiz Brugu\u00e9s A, Sibaud V, Herbault-Barr\u00e9s B, Betrian S, Korakis I, De Bataille C et al (2020) Sicca syndrome induced by immune checkpoint inhibitor therapy: optimal management still pending. Oncologist 25:e391\u2013e395","journal-title":"Oncologist"},{"key":"10945_CR49","doi-asserted-by":"crossref","first-page":"1417444","DOI":"10.3389\/fimmu.2024.1417444","volume":"15","author":"C Pellegrino","year":"2024","unstructured":"Pellegrino C, D\u2019Antonio C, Ierino D, Onesti CE, Aschelter AM, Santini D et al (2024) Sjogren syndrome induced by anti PDL-1 treatment for TNBC: case report and review of literature. Front Immunol 15:1417444","journal-title":"Front Immunol"},{"key":"10945_CR50","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/ijd.17683","volume":"64","author":"M Pozsgai","year":"2025","unstructured":"Pozsgai M, Sebastian UF, Olah P, Nemeth V, Gyulai R, Lengyel Z (2025) Cutaneous side effects of PD-1 inhibitors: a single-center retrospective study. Int J Dermatol 64:1066\u20131078","journal-title":"Int J Dermatol"},{"key":"10945_CR51","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3389\/fonc.2020.00420","volume":"10","author":"S Pringle","year":"2020","unstructured":"Pringle S, van der Vegt B, Wang X, van Bakelen N, Hiltermann TJN, Spijkervet FKL et al (2020) Lack of conventional acinar cells in parotid salivary gland of patient taking an anti-PD-L1 immune checkpoint inhibitor. Front Oncol 10:420","journal-title":"Front Oncol"},{"issue":"Suppl 118","key":"10945_CR52","first-page":"114","volume":"37","author":"M Ramos-Casals","year":"2019","unstructured":"Ramos-Casals M, Maria A, Su\u00e1rez-Almazor ME, Lambotte O, Fisher BA, Hern\u00e1ndez-Molina G et al (2019) Sicca\/Sj\u00f6gren\u2019s syndrome triggered by PD-1\/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR). Clin Exp Rheumatol 37(Suppl 118):114\u201322","journal-title":"Clin Exp Rheumatol"},{"key":"10945_CR53","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/iju5.12573","volume":"6","author":"T Segawa","year":"2023","unstructured":"Segawa T, Motoshima T, Yatsuda J, Kurahashi R, Fukushima Y, Murakami Y et al (2023) Sicca syndrome during ipilimumab and nivolumab therapy for metastatic renal cell carcinoma. IJU Case Rep 6:147\u2013149","journal-title":"IJU Case Rep"},{"key":"10945_CR54","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1186\/s13256-022-03663-6","volume":"16","author":"SR Simeni Njonnou","year":"2022","unstructured":"Simeni Njonnou SR, Aspeslagh S, Ntsama Essomba MJ, Racu ML, Kemta Lekpa F, Vandergheynst F (2022) Isolated adrenocorticotropic hormone deficiency and sialadenitis associated with nivolumab: a case report. J Med Case Rep 16:456","journal-title":"J Med Case Rep"},{"key":"10945_CR55","doi-asserted-by":"crossref","first-page":"1091459","DOI":"10.3389\/fonc.2023.1091459","volume":"13","author":"K Song","year":"2023","unstructured":"Song K, Dong H, Jiang S, Xu X, Zhang C, Chen Q et al (2023) Case report: A rare case of sintilimab-induced gastric stenosis and literature review. Front Oncol 13:1091459","journal-title":"Front Oncol"},{"key":"10945_CR56","doi-asserted-by":"crossref","first-page":"e00322","DOI":"10.1002\/rcr2.322","volume":"6","author":"S Takahashi","year":"2018","unstructured":"Takahashi S, Chieko X, Sakai T, Hirose S, Nakamura M (2018) Nivolumab-induced sialadenitis. Respirol Case Rep 6:e00322","journal-title":"Respirol Case Rep"},{"key":"10945_CR57","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1093\/annonc\/mdx531","volume":"28","author":"D Teyssonneau","year":"2017","unstructured":"Teyssonneau D, Cousin S, Italiano A (2017) Gougerot-Sjogren-like syndrome under PD-1 inhibitor treatment. Ann Oncol 28:3108","journal-title":"Ann Oncol"},{"key":"10945_CR58","doi-asserted-by":"crossref","first-page":"e32731","DOI":"10.1097\/MD.0000000000032731","volume":"102","author":"T Wei","year":"2023","unstructured":"Wei T, Wang Z, Liu X (2023) Adverse reactions and efficacy of camrelizumab in patients with lung adenocarcinoma with high PD-L1 expression: a case report. Medicine (Baltimore) 102:e32731","journal-title":"Medicine (Baltimore)"},{"key":"10945_CR59","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/07357907.2021.1971241","volume":"39","author":"OA Yildirim","year":"2021","unstructured":"Yildirim OA, Poyraz K, Erdur E, Can C, Gundogan C, Guzel Y et al (2021) Nivolumab-related dry mouth and dry eye: cross-sectional study. Cancer Invest 39:797\u2013807","journal-title":"Cancer Invest"},{"key":"10945_CR60","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","volume":"44","author":"L Spain","year":"2016","unstructured":"Spain L, Diem S, Larkin J (2016) Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44:51\u201360","journal-title":"Cancer Treat Rev"},{"key":"10945_CR61","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","volume":"19","author":"FS Hodi","year":"2018","unstructured":"Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL et al (2018) Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol 19:1480\u20131492","journal-title":"Lancet Oncol"},{"key":"10945_CR62","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","volume":"30","author":"JS Weber","year":"2012","unstructured":"Weber JS, K\u00e4hler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30:2691\u20132697","journal-title":"J Clin Oncol"},{"issue":"6","key":"10945_CR63","doi-asserted-by":"crossref","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","volume":"9","author":"JR Brahmer","year":"2021","unstructured":"Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB et al (2021) Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer 9(6):e002435","journal-title":"J Immunother Cancer"},{"key":"10945_CR64","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S et al (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139\u2013148","journal-title":"Eur J Cancer"},{"key":"10945_CR65","doi-asserted-by":"crossref","first-page":"108497","DOI":"10.1016\/j.clim.2020.108497","volume":"217","author":"CP Mavragani","year":"2020","unstructured":"Mavragani CP, Moutsopoulos HM (2020) Sicca syndrome following immune checkpoint inhibition. Clin Immunol 217:108497","journal-title":"Clin Immunol"},{"key":"10945_CR66","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/rheumatology\/keaa471","volume":"60","author":"S Finzel","year":"2021","unstructured":"Finzel S, Jousse-Joulin S, Costantino F, H\u00e1nov\u00e1 P, Hocevar A, Iagnocco A et al (2021) Patient-based reliability of the outcome measures in rheumatology (OMERACT) ultrasound scoring system for salivary gland assessment in patients with Sj\u00f6gren\u2019s syndrome. Rheumatology (Oxford) 60:2169\u20132176","journal-title":"Rheumatology (Oxford)"},{"key":"10945_CR67","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaut.2009.10.004","volume":"34","author":"MI Christodoulou","year":"2010","unstructured":"Christodoulou MI, Kapsogeorgou EK, Moutsopoulos HM (2010) Characteristics of the minor salivary gland infiltrates in Sj\u00f6gren\u2019s syndrome. J Autoimmun 34:400\u2013407","journal-title":"J Autoimmun"},{"key":"10945_CR68","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1001\/archinte.1991.00400060085014","volume":"151","author":"PC Fox","year":"1991","unstructured":"Fox PC, Atkinson JC, Macynski AA, Wolff A, Kung DS, Valdez IH et al (1991) Pilocarpine treatment of salivary gland hypofunction and dry mouth (xerostomia). Arch Intern Med 151:1149\u20131152","journal-title":"Arch Intern Med"},{"key":"10945_CR69","unstructured":"National Cancer Institute (2025) Common terminology criteria for adverse events (CTCAE) v6.0. Available from: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v6.pdf. Accessed 20 June 2026"},{"key":"10945_CR70","doi-asserted-by":"crossref","first-page":"633032","DOI":"10.3389\/fonc.2021.633032","volume":"11","author":"Y Fan","year":"2021","unstructured":"Fan Y, Xie W, Huang H, Wang Y, Li G, Geng Y et al (2021) Association of immune related adverse events with efficacy of immune checkpoint inhibitors and overall survival in cancers: a systemic review and meta-analysis. Front Oncol 11:633032","journal-title":"Front Oncol"},{"key":"10945_CR71","doi-asserted-by":"crossref","first-page":"1281645","DOI":"10.3389\/fonc.2024.1281645","volume":"14","author":"Y Liang","year":"2024","unstructured":"Liang Y, Xu H, Liu F, Li L, Lin C, Zhang Y et al (2024) Immune-related adverse events and their effects on survival outcomes in patients with non-small cell lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Front Oncol 14:1281645","journal-title":"Front Oncol"},{"key":"10945_CR72","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12916-020-01549-2","volume":"18","author":"X Zhou","year":"2020","unstructured":"Zhou X, Yao Z, Yang H, Liang N, Zhang X, Zhang F (2020) Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med 18:87","journal-title":"BMC Med"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10945-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-10945-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10945-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T18:03:36Z","timestamp":1784052216000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-10945-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":72,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10945"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-10945-y","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"18 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics, consent to participate, and consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"723"}}